


(6) 20. The pharmaceutical composition of claim *19*, wherein said composition has anti-inflammatory activity.

(7) 21. The pharmaceutical composition of claim *19*, wherein said composition has analgesic activity.


(8) 22. The pharmaceutical composition of claim *19*, wherein said composition is used in the treatment of rheumatic diseases, immunological disorders, and moderate to medium painful conditions.

(9) 23. The composition of claim *19*, wherein said composition is used in the treatment of diseases affecting the cardiovascular system, senile dementia, myocardial and brain ischemia, and arterial thrombosis.


24. A process for the preparation of nitric esters according to claim 1 and having the following general formula:




where A and B are chosen among hydrogen, linear or branched, substituted or non substituted alkyl chains,
where M is chosen among




(XXX)



(XXXI)




(XXXII)




(XXXIII)

where R is chosen among:



(II)




(III)

(X)

Y is chosen among oxygen, NH, NR₁, where R₁ is a linear or branched alkyl group, and n is comprised between 1 and 10,

comprising the following steps:


(a) contacting a sodium salt of derivatives having the following general formula:




where M is chosen among the following structures: (XXX), (XXXI), (XXXII),




where R is chosen among the following structures:



(II)



(III)



or contacting derivatives of structure (VIA) functionalized to the carboxylic group;

(b) reacting the sodium salt of said derivatives (VIA) or of said derivatives (VIA) functionalized to the carboxylic group, with a compound having the following general formula:



where:


R_4 is chosen among chlorine, bromine, NHR_5 with R_5 hydrogen, linear or branched alkyl chain, A and B are chosen among hydrogen, linear or branched, substituted or non substituted alkyl chains, R_3 is chosen among chlorine, bromine and iodine, and n is comprised between 1 and 10, to produce monomeric esters or amides; and

(c) reacting said monomeric esters or said amides with a nitrating agent to produce the nitric esters of derivatives (IA).

25. The process of claim 24, wherein said carboxylic group is an acyclic chloride or anhydride chloride.




26. The process of claim 24, wherein said nitrating agent is $AgNO_3$.


27. A process for the preparation of nitric esters according to claim 1 and having the following general formula:



where A and B are chosen among hydrogen, linear or branched, substituted or non substituted alkyl chains,


M is chose among






(XXXIII)


where R is chosen among:



(X)



(II)




(III)

Y is chosen among oxygen, NH, NR₁, where R₁ is a linear or branched alkyl group, and n is comprised between 1 and 10,


comprising the following steps:

(a) contacting a sodium salt of derivatives having the following general formula:




(VIA)

where M is chosen among the following structures: (XXX), (XXXI), (XXXII),



(XXXIII)

where R is chosen among the following structures:




(II)

(X)

(III)

or contacting derivatives of structure (VIA) functionalized to the carboxylic group;

(b) reacting the sodium salt of said derivatives (VIA) or of said derivatives (VIA) functionalized to the carboxylic group, with a composition having the following general formula:



(VIII)

where:

R₄ is chosen among chlorine, bromine, NHR₅ with R₅ hydrogen, linear or branched alkyl chain, A and B are chosen among hydrogen, linear or branched, substituted or non substituted alkyl chains, and n is comprised between 1 and 10, to produce monomeric esters or amides;

(c) reacting said monomeric esters or said amides with an halogenating compound, to produce said monomeric esters or said amides, characterized by the presence of a terminal halogen group; and

(d) reacting said monomeric esters or said amides, characterized by the presence of a terminal halogen group, with a nitrating agent, to produce nitric esters of derivatives (IA).

28. The process of claim 27, wherein said carboxylic group is an acyclic chloride or anhydride chloride.

29. The process of claim 27, wherein said halogenating compound is PBr₃.

30. The process of claim 27, wherein said nitrating agent is AgNO₃.

REMARKS

This Preliminary Amendment is being submitted to make the claims conform to standard U.S. practice. The pending claims are 1-10 and 19-30. No new matter has been